Motors Effects in Parkinson's Disease by the action of 5-HT2a/c antagonistic drug mediated by ELF2-alpha factor phosphorylation pathway in humans. A Double-Blind Randomized Controlled Trial.

niversidade Federal da Integração Latino-Americana do Brasil (UNILA).0 个研究点开始时间: 2020年8月26日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Individuals with PD clinically diagnosed according to the London Brain Bank criteria. Individuals who voluntarily agree with the procedures and information of the Free and Informed Consent Form. Have cognitive function that allows the understanding of past information by the researcher during the tests (Mini Mental State Examination). Do not present conditions that hinder or impede the movement of the upper limbs, such as: surgeries in the last 12 months; musculotendinosus injuries; fractures; use of prostheses or prostheses; other associated neurological or neurodegenerative conditions; etc. Individuals classified in phase 3 of the Hoeh and Yahr scale.

•Withdrawal from participation in the research. Incomplete completion of the instruments. Individuals with treatment abandonment. Patients with symptoms of parkinsonism induced by exogenous intoxication, infectious, vascular, metabolic, genetic causes, other degenerative diseases or by drugs - such as dopaminergic receptor blockers, anticholinesterases, anticonvulsants, antiarrhythmics, reserpine, tetrabenazine, alfamethyldopa, lithium and fluoxetine. Patients who do not want to stop using monoamine oxidase (MAO) inhibitor drugs. Patients who do not interrupt the use of monoamine oxity (MAO) inhibitor drugs in 15 days before the start of the survey. MAO inhibitors are considered, among others, the following medications: Phenelzine; Iproniazid; Isocarboxazide; Harmalina; Nialamide; Pargyline; Selegiline; Toloxatone; Tranilcipromina. Patients who need to use the linezolid antibiotic, digoxin or phenytoin during the experiment. Diabetic patients or patients with other chronic diseases. Individuals with cardiac disorders or in the recovery phase of an acute myocardial infarction . Patients with reports of psychological disorders such as schizophrenia or bipolar disorder. Patients with renal or hepatic impairment. Pregnant or lactating patients. Patients who have changed the treatment of PD in the past 03 months.

发起方

niversidade Federal da Integração Latino-Americana do Brasil (UNILA).